Sat, 12th Dec 2020 13:24
(Repeats without changes to text)
Dec 12 (Reuters) - Astrazeneca Plc will acquire U.S.
based Alexion Pharmaceuticals in a $39 billion deal,
the company said in a statement on Saturday.
Alexion shareholders will receive $60 in cash and 2.1243
AstraZeneca American Depositary Shares per Alexion share, the
company said.
(Reporting by Aishwarya Nair in Bengaluru; Editing by Toby
Chopra)
(Correcting company name in headline)
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...
Astrazeneca (AZN)